News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
MarketBeat Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
BlackRock, Inc. has disclosed a 6.7% ownership stake in Immuneering Corp (IMRX), as reported in a Schedule 13G SEC filing. This position amounts to 4,356,235 shares of Immuneering’s Class A stock as of June 30, 2026. BlackRock holds sole voting power over 4,314,766 shares …
Immuneering Corporation announced grants of inducement awards to its new Chief Financial Officer, Andrew Gengos, and a non-executive employee. Mr. Gengos received an option to purchase 650,000 shares of common stock with a per-share exercise price of $4.78, vesting over four years. An additional …
Immuneering Corporation (NASDAQ: IMRX) has granted a 650,000-share option to its new CFO, Andrew Gengos, as an inducement award, with an exercise price of $4.78 per share. This ten-year option, alongside a smaller grant to a non-executive employee, vests over four years and was …
Immuneering Corp (IMRX) has granted its CFO, Andrew Gengos, stock options for 650,000 shares of Class A Common Stock. The exercise price is set at $4.78 per share, and the options are set to expire on July 16, 2036. These options will vest monthly …
Immuneering Corp's Chief Financial Officer, Andrew Gengos, has reported direct ownership of 225,000 shares of the company's Class A Common Stock. This disclosure is a Form 3 filing, which is an initial statement of beneficial ownership, and does not indicate any open-market transactions or …
Search by ticker symbol or company name and select a result to open its chart.